Therapeutic indications

Afamelanotide is indicated for:

Prevention of phototoxicity in erythropoietic protoporphyria (EPP)

Population group: both men and women, only adults (18 - 65 years old)

Afamelanotide is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

For this indication, competent medicine agencies globally authorize below treatments (click for details):


Afamelanotide is contraindicated in the following cases:

Renal impairment

Renal failure

Hepatic impairment

Hepatic insufficiency

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines